DelfaGLP-1 Atlas

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd.

20 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

20

Trials led

9

Active

4,940

Total enrollment

33

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
4
Phase 1/2
3
Phase 2
4
Phase 3
9

Trials by status

Recruiting
5
Active, not recruiting
4
Completed
11

Trials led

A Study of IBI362 in Participants With Type 2 DiabetesBMI ≥23Ph 3Completed731
A Study of IBI362 in Participants With Obesity or OverweightBMI ≥28Ph 3Completed610
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）BMI ≥27Ph 3Active, not recruiting479
A Study of IBI362 9 mg in Chinese Adults With ObesityBMI ≥30Ph 3Active, not recruiting462
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityBMI ≥28Ph 3Active, not recruiting349
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity—Ph 3Recruiting336
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsBMI ≥28Ph 2Completed328
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseHbA1c ≤10.5%Ph 3Completed319
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2BMI ≥28Ph 3Recruiting260
A Study of IBI362 in Chinese Patients With Type 2 DiabetesHbA1c 7-10.5%Ph 2Completed252
A Study of IBI362 in Chinese Adolescents With Obesity or OverweightBMI 586-2018Ph 3Recruiting180
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)BMI ≥25Ph 2Recruiting165
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityBMI ≥28Ph 2Recruiting141
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityBMI ≥32.5Ph 1/2Active, not recruiting98
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsBMI ≥24Ph 1/2Completed60
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsBMI 24-30Ph 1Completed48
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMBMI ≤35Ph 1/2Completed42
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityBMI 586-2018Ph 1Completed36
Clinical Study of IBI362 in Healthy Chinese Male SubjectsBMI ≤26Ph 1Completed24
Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmenteGFR ≥90Ph 1Completed20